An unexpected finding in preclinical platelet studies by Baker Institute researchers could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers.
One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research.
Researchers in Finland have discovered a drug combination that collaborates with the cancer cells' own MYC oncoprotein, which in large quantities causes self-destruction of the cancer cells. When this combination is enhanced with immune system-boosting anti-PD-1 therapy, a more effective and long-lasting therapeutic effect can be seen in mice. These findings pave the way for new treatment combination strategies to harness the body's natural defenses to fight cancer.
In a Psycho-Oncology study of 28 women who were being treated for breast cancer and were participating in focus groups, White participants noted that having other breast cancer survivors in their support network was essential for meeting their social support needs. Black participants did not reference other breast cancer survivors as part of their networks, however.
Tumor cells use a certain type of immune cells, the so-called neutrophils, to enhance their ability to form metastases. Scientists have deciphered the mechanisms of this collaboration and found strategies for blocking them. This is reported by researchers from the University of Basel and the University Hospital of Basel in the scientific journal Nature.
Researchers from the University of Alberta may have found a way to make chemotherapy more effective at treating cancer while blocking its harmful side-effects on the heart.
Researchers at Washington University School of Medicine in St. Louis may have found a path toward improving the effectiveness of chemotherapy in people with breast or ovarian cancer caused by defects in one of the BRCA genes. The researchers identified a pair of genes that operate in parallel to BRCA and may increase susceptibility to chemotherapy drugs.
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare and one common form.
Some types of cancer cannot be treated with classical chemotherapy. Scientists from Inserm, CNRS, Sorbonne University, PSL university, University Grenoble Alpes and ESRF, the European Synchrotron, are working on a metallorganic molecule as an antitumor drug. Their research has given thorough insights into its mechanism in attacking cancer cells. This study is published in Angewandte Chemie.
Studies have found that racial and ethnic minorities are less likely to receive end-of-life palliative care than their counterparts. A new study conducted by investigators at Brigham and Women's Hospital set out to understand why and has revealed that site of care may be a key contributing factor to this difference among patients with advanced, metastatic cancer.